173 related articles for article (PubMed ID: 2541344)
1. Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules.
Traunecker A; Schneider J; Kiefer H; Karjalainen K
Nature; 1989 May; 339(6219):68-70. PubMed ID: 2541344
[TBL] [Abstract][Full Text] [Related]
2. Janusin: new molecular design for bispecific reagents.
Traunecker A; Lanzavecchia A; Karjalainen K
Int J Cancer Suppl; 1992; 7():51-2. PubMed ID: 1428404
[TBL] [Abstract][Full Text] [Related]
3. Soluble CD4 molecules neutralize human immunodeficiency virus type 1.
Traunecker A; Lüke W; Karjalainen K
Nature; 1988 Jan; 331(6151):84-6. PubMed ID: 2829024
[TBL] [Abstract][Full Text] [Related]
4. HIV infection is blocked in vitro by recombinant soluble CD4.
Fisher RA; Bertonis JM; Meier W; Johnson VA; Costopoulos DS; Liu T; Tizard R; Walker BD; Hirsch MS; Schooley RT
Nature; 1988 Jan; 331(6151):76-8. PubMed ID: 2829022
[TBL] [Abstract][Full Text] [Related]
5. A soluble form of CD4 (T4) protein inhibits AIDS virus infection.
Deen KC; McDougal JS; Inacker R; Folena-Wasserman G; Arthos J; Rosenberg J; Maddon PJ; Axel R; Sweet RW
Nature; 1988 Jan; 331(6151):82-4. PubMed ID: 3257544
[TBL] [Abstract][Full Text] [Related]
6. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation.
Hussey RE; Richardson NE; Kowalski M; Brown NR; Chang HC; Siliciano RF; Dorfman T; Walker B; Sodroski J; Reinherz EL
Nature; 1988 Jan; 331(6151):78-81. PubMed ID: 2829023
[TBL] [Abstract][Full Text] [Related]
7. Designing CD4 immunoadhesins for AIDS therapy.
Capon DJ; Chamow SM; Mordenti J; Marsters SA; Gregory T; Mitsuya H; Byrn RA; Lucas C; Wurm FM; Groopman JE
Nature; 1989 Feb; 337(6207):525-31. PubMed ID: 2536900
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 neutralization by chimeric CD4-CG10 polypeptides fused to human IgG1.
Meyuhas R; Noy H; Montefiori DC; Denisova G; Gershoni JM; Gross G
Mol Immunol; 2005 May; 42(9):1099-109. PubMed ID: 15829299
[TBL] [Abstract][Full Text] [Related]
9. Identification of human CD4 residues affecting class II MHC versus HIV-1 gp120 binding.
Clayton LK; Sieh M; Pious DA; Reinherz EL
Nature; 1989 Jun; 339(6225):548-51. PubMed ID: 2543930
[TBL] [Abstract][Full Text] [Related]
10. Prevention of HIV-1 IIIB infection in chimpanzees by CD4 immunoadhesin.
Ward RH; Capon DJ; Jett CM; Murthy KK; Mordenti J; Lucas C; Frie SW; Prince AM; Green JD; Eichberg JW
Nature; 1991 Aug; 352(6334):434-6. PubMed ID: 1907354
[TBL] [Abstract][Full Text] [Related]
11. CD4 immunoadhesins in anti-HIV therapy: new developments.
Chamow SM; Duliege AM; Ammann A; Kahn JO; Allen JD; Eichberg JW; Byrn RA; Capon DJ; Ward RH; Ashkenazi A
Int J Cancer Suppl; 1992; 7():69-72. PubMed ID: 1428410
[TBL] [Abstract][Full Text] [Related]
12. The envelope glycoprotein of the human immunodeficiency virus binds to the immunoglobulin-like domain of CD4.
Landau NR; Warton M; Littman DR
Nature; 1988 Jul; 334(6178):159-62. PubMed ID: 3260352
[TBL] [Abstract][Full Text] [Related]
13. Domain-switched mouse IgM/IgG2b hybrids indicate individual roles for C mu 2, C mu 3, and C mu 4 domains in the regulation of the interaction of IgM with complement C1q.
Chen FH; Arya SK; Rinfret A; Isenman DE; Shulman MJ; Painter RH
J Immunol; 1997 Oct; 159(7):3354-63. PubMed ID: 9317134
[TBL] [Abstract][Full Text] [Related]
14. Mapping of the human immunodeficiency virus type 2 envelope glycoprotein CD4 binding region and fusion domain with truncated proteins expressed by recombinant vaccinia viruses.
Otteken A; Voss G; Hunsmann G
Virology; 1993 May; 194(1):37-43. PubMed ID: 8480426
[TBL] [Abstract][Full Text] [Related]
15. Soluble gC1q-R/p33, a cell protein that binds to the globular "heads" of C1q, effectively inhibits the growth of HIV-1 strains in cell cultures.
Szabó J; Cervenák L; Tóth FD; Prohászka Z; Horváth L; Kerekes K; Beck Z; Bácsi A; Erdei A; Peerschke EI; Füst G; Ghebrehiwet B
Clin Immunol; 2001 May; 99(2):222-31. PubMed ID: 11318594
[TBL] [Abstract][Full Text] [Related]
16. Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3-directed monoclonal antibodies.
Potts BJ; Field KG; Wu Y; Posner M; Cavacini L; White-Scharf M
Virology; 1993 Nov; 197(1):415-9. PubMed ID: 8212576
[TBL] [Abstract][Full Text] [Related]
17. Addition of a mu-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4.
Smith RI; Coloma MJ; Morrison SL
J Immunol; 1995 Mar; 154(5):2226-36. PubMed ID: 7868896
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein.
Bosch B; Blanco J; Pauls E; Clotet-Codina I; Armand-Ugón M; Grigorov B; Muriaux D; Clotet B; Darlix JL; Esté JA
Antimicrob Agents Chemother; 2005 Oct; 49(10):4296-304. PubMed ID: 16189111
[TBL] [Abstract][Full Text] [Related]
19. A matched set of rat/mouse chimeric antibodies. Identification and biological properties of rat H chain constant regions mu, gamma 1, gamma 2a, gamma 2b, gamma 2c, epsilon, and alpha.
Brüggemann M; Teale C; Clark M; Bindon C; Waldmann H
J Immunol; 1989 May; 142(9):3145-50. PubMed ID: 2496159
[TBL] [Abstract][Full Text] [Related]
20. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.
Wu L; Gerard NP; Wyatt R; Choe H; Parolin C; Ruffing N; Borsetti A; Cardoso AA; Desjardin E; Newman W; Gerard C; Sodroski J
Nature; 1996 Nov; 384(6605):179-83. PubMed ID: 8906795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
